Severity of Coronavirus Disease 19: A Profile of Inflammatory Markers in Iraqi Patients
Main Article Content
Abstract
Introduction: Accumulating evidence indicates that inflammatory responses play a major role in the development and/or severity of coronavirus disease 2019 (COVID-19). Therefore, a retrospective, cross-sectional study was performed to provide an inflammatory profile in COVID-19. Methods: The study included 139 patients infected with COVID-19, who were admitted to inpatient wards and intensive care units in Baghdad Teaching Hospital. There were 105 patients suffering from non-severe illness and 34 patients had severe disease. This study simultaneously evaluated six peripheral blood markers of inflammation to determine their predictive value in COVID-19 severity. These were C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), ferritin, D-dimer, lactate dehydrogenase (LDH) and neutrophil-to-lymphocyte ratio (NLR). Results: The medians of age, CRP, ESR, ferritin, D-dimer and NLR were significantly elevated in severe cases of COVID-19 compared to non-severe cases. The LDH also tended to have increased levels in severe cases but the difference was not significant compared to non-severe cases. Logistic regression analysis demonstrated that D-dimer was the most significant risk factor, followed by NLR, ferritin and CRP. Receiver operating characteristic (ROC) curve analysis identified that the best cut-off values of CRP, ESR, ferritin, D-dimer, LDH and NLR for predicting severity in COVID-19 patients were 22.7 mg/L, 59.5 mm/h, 719.4 ng/mL, 367.5 ng/mL, 468.5 U/L and 12.9, respectively. Conclusion: Age and the inflammatory markers CRP, ESR, ferritin, D-dimer, and NLR showed higher medians in severe cases of COVID-19 compared to non-severe cases. In this context, D-dimer and NLR are suggested to be important predictive markers of severe disease.
Downloads
Article Details
References
World Health Organization (WHO). Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV) [Internet]. Geneva, Switzerland. 2020 [cited 2021 Mar 12]. p. 1–6. Available from: https://www.who.int/news/item/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov)
Li H, Liu SM, Yu XH, Tang SL, Tang CK. Coronavirus disease 2019 (COVID-19): current status and future perspectives. Int J Antimicrob Agents [Internet]. 2020 May 1 [cited 2020 Aug 22];55(5):105951. Available from: /pmc/articles/PMC7139247/?report=abstract
WHO. WHO Coronavirus Disease (COVID-19) Dashboard | WHO Coronavirus Disease (COVID-19) Dashboard [Internet]. Who.int. 2021 [cited 2021 Mar 12]. Available from: https://covid19.who.int/
Li J, Huang DQ, Zou B, Yang H, Hui WZ, Rui F, et al. Epidemiology of COVID-19: A systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes. J Med Virol [Internet]. 2020 Aug 25 [cited 2020 Sep 8];jmv.26424. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.26424
Elezkurtaj S, Greuel S, Ihlow J, Michaelis EG, Bischoff P, Kunze CA, et al. Causes of death and comorbidities in hospitalized patients with COVID-19. Sci Rep [Internet]. 2021 Dec 19 [cited 2021 Mar 11];11(1):4263. Available from: http://www.nature.com/articles/s41598-021-82862-5
García LF. Immune Response, Inflammation, and the Clinical Spectrum of COVID-19 [Internet]. Vol. 11, Frontiers in Immunology. Frontiers Media S.A.; 2020 [cited 2021 Mar 13]. p. 1441. Available from: /pmc/articles/PMC7308593/
Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Møller R, et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell [Internet]. 2020 May 28 [cited 2021 Mar 13];181(5):1036-1045.e9. Available from: https://pubmed.ncbi.nlm.nih.gov/32416070/
Ghahramani S, Tabrizi R, Lankarani KB, Kashani SMA, Rezaei S, Zeidi N, et al. Laboratory features of severe vs. non-severe COVID-19 patients in Asian populations: A systematic review and meta-analysis [Internet]. Vol. 25, European Journal of Medical Research. BioMed Central; 2020 [cited 2021 Mar 13]. p. 30. Available from: https://eurjmedres.biomedcentral.com/articles/10.1186/s40001-020-00432-3
Ji P, Zhu J, Zhong Z, Li H, Pang J, Li B, et al. Association of elevated inflammatory markers and severe COVID-19. Medicine (Baltimore) [Internet]. 2020 Nov 20 [cited 2021 Mar 12];99(47):e23315. Available from: https://journals.lww.com/10.1097/MD.0000000000023315
World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected: interim guidance 28 January 2020 [Internet]. Who. 2020. p. 10. Available from: WHO/2019-nCoV/clinical/2020.5%0ACC BY-NC-SA 3.0 IGO%0AWHO/2019-nCoV/clinical/2020.5%0ACC BY-NC-SA 3.0 IGO%0Ahttps://apps.who.int/iris/handle/10665/330893e
Gandhi RT, Lynch JB, del Rio C. Mild or Moderate Covid-19. Solomon CG, editor. N Engl J Med [Internet]. 2020 Oct 29 [cited 2021 Mar 16];383(18):1757–66. Available from: http://www.nejm.org/doi/10.1056/NEJMcp2009249
Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study. BMJ [Internet]. 2020 Mar 26 [cited 2021 Mar 14];368. Available from: https://pubmed.ncbi.nlm.nih.gov/32217556/
Chen TL, Dai Z, Mo P, Li X, Ma Z, Song S, et al. Clinical Characteristics and Outcomes of Older Patients with Coronavirus Disease 2019 (COVID-19) in Wuhan, China: A Single-Centered, Retrospective Study. Journals Gerontol - Ser A Biol Sci Med Sci [Internet]. 2020 Jun 5 [cited 2021 Mar 14];75(9):1788–95. Available from: https://pubmed.ncbi.nlm.nih.gov/32279081/
Farghaly S, Makboul M. Correlation between age, sex, and severity of Coronavirus disease-19 based on chest computed tomography severity scoring system. Egypt J Radiol Nucl Med [Internet]. 2021 Dec 1 [cited 2021 Mar 14];52(1):23. Available from: https://ejrnm.springeropen.com/articles/10.1186/s43055-021-00408-1
Starke KR, Petereit-Haack G, Schubert M, Kämpf D, Schliebner A, Hegewald J, et al. The age-related risk of severe outcomes due to covid-19 infection: A rapid review, meta-analysis, and meta-regression. Int J Environ Res Public Health [Internet]. 2020 Aug 2 [cited 2021 Mar 14];17(16):1–24. Available from: /pmc/articles/PMC7460443/
Yao Y, Cao J, Wang Q, Shi Q, Liu K, Luo Z, et al. D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: A case control study. J Intensive Care [Internet]. 2020 Jul 10 [cited 2021 Mar 18];8(1):49. Available from: https://jintensivecare.biomedcentral.com/articles/10.1186/s40560-020-00466-z
Ozen M, Yilmaz A, Cakmak V, Beyoglu R, Oskay A, Seyit M, et al. D-Dimer as a potential biomarker for disease severity in COVID-19. Am J Emerg Med [Internet]. 2021 Feb 1 [cited 2021 Mar 18];40:55–9. Available from: https://pubmed.ncbi.nlm.nih.gov/33348224/
Linkins LA, Takach Lapner S. Review of D-dimer testing: Good, Bad, and Ugly [Internet]. Vol. 39, International Journal of Laboratory Hematology. Blackwell Publishing Ltd; 2017 [cited 2021 Mar 18]. p. 98–103. Available from: https://pubmed.ncbi.nlm.nih.gov/28447414/
Shorr AF, Thomas SJ, Alkins SA, Fitzpatrick TM, Ling GS. D-dimer correlates with proinflammatory cytokine levels and outcomes in critically ILL patients. Chest [Internet]. 2002 Apr 1 [cited 2021 Mar 18];121(4):1262–8. Available from: http://journal.chestnet.org/article/S0012369215343099/fulltext
Notz Q, Schmalzing M, Wedekink F, Schlesinger T, Gernert M, Herrmann J, et al. Pro- and Anti-Inflammatory Responses in Severe COVID-19-Induced Acute Respiratory Distress Syndrome—An Observational Pilot Study. Front Immunol [Internet]. 2020 Oct 6 [cited 2021 Mar 18];11:581338. Available from: https://www.frontiersin.org/article/10.3389/fimmu.2020.581338/full
Kaur S, Bansal R, Kollimuttathuillam S, Gowda AM, Singh B, Mehta D, et al. The looming storm: Blood and cytokines in COVID-19 [Internet]. Vol. 46, Blood Reviews. Churchill Livingstone; 2020 [cited 2021 Mar 18]. p. 100743. Available from: /pmc/articles/PMC7431319/
Chaplin DD. Overview of the immune response. J Allergy Clin Immunol [Internet]. 2010 Feb [cited 2021 Mar 18];125(2 SUPPL. 2):S3. Available from: /pmc/articles/PMC2923430/
Aktas G, Sit M, Dikbas O, Erkol H, Altinordu R, Erkus E, et al. Elevated neutrophil-to-lymphocyte ratio in the diagnosis of Hashimoto’s thyroiditis. Rev Assoc Med Bras [Internet]. 2017 Dec 1 [cited 2021 Mar 18];63(12):1065–8. Available from: http://dx.doi.org/10.1590/1806-9282.63.12.1065
Song H, Kim HJ, Park KN, Kim SH, Oh SH, Youn CS. Neutrophil to lymphocyte ratio is associated with in-hospital mortality in older adults admitted to the emergency department. Am J Emerg Med [Internet]. 2021 Feb 1 [cited 2021 Mar 19];40:133–7. Available from: https://pubmed.ncbi.nlm.nih.gov/32008828/
Yang AP, Liu J ping, Tao W qiang, Li H ming. The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. Int Immunopharmacol [Internet]. 2020 Jul 1 [cited 2021 Mar 19];84:106504. Available from: /pmc/articles/PMC7152924/
Li X, Liu C, Mao Z, Xiao M, Wang L, Qi S, et al. Predictive values of neutrophil-to-lymphocyte ratio on disease severity and mortality in COVID-19 patients: a systematic review and meta-analysis. Crit Care [Internet]. 2020 Dec 1 [cited 2021 Mar 19];24(1):647. Available from: https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03374-8
Jimeno S, Ventura PS, Castellano JM, García-Adasme SI, Miranda M, Touza P, et al. Prognostic implications of neutrophil-lymphocyte ratio in COVID-19. Eur J Clin Invest [Internet]. 2021 Jan 1 [cited 2021 Mar 19];51(1). Available from: https://pubmed.ncbi.nlm.nih.gov/32918295/
Sproston NR, Ashworth JJ. Role of C-reactive protein at sites of inflammation and infection [Internet]. Vol. 9, Frontiers in Immunology. Frontiers Media S.A.; 2018 [cited 2021 Mar 19]. p. 754. Available from: /pmc/articles/PMC5908901/
Smilowitz NR, Kunichoff D, Garshick M, Shah B, Pillinger M, Hochman JS, et al. C-reactive protein and clinical outcomes in patients with COVID-19. Eur Heart J [Internet]. 2021 Jan 15 [cited 2021 Mar 19]; Available from: https://pubmed.ncbi.nlm.nih.gov/33448289/
Wang L. C-reactive protein levels in the early stage of COVID-19. Med Mal Infect. 2020 Jun 1;50(4):332–4.
Lapić I, Rogić D, Plebani M, Plebani M. Erythrocyte sedimentation rate is associated with severe coronavirus disease 2019 (COVID-19): A pooled analysis [Internet]. Vol. 58, Clinical Chemistry and Laboratory Medicine. De Gruyter; 2020 [cited 2021 Mar 19]. p. 1146–8. Available from: https://pubmed.ncbi.nlm.nih.gov/32386190/
Kappert K, Jahić A, Tauber R. Assessment of serum ferritin as a biomarker in COVID-19: bystander or participant? Insights by comparison with other infectious and non-infectious diseases. Biomarkers [Internet]. 2020 Nov 16 [cited 2021 Mar 19];25(8):616–25. Available from: https://www.tandfonline.com/doi/full/10.1080/1354750X.2020.1797880
Gómez-Pastora J, Weigand M, Kim J, Wu X, Strayer J, Palmer AF, et al. Hyperferritinemia in critically ill COVID-19 patients – Is ferritin the product of inflammation or a pathogenic mediator? [Internet]. Vol. 509, Clinica Chimica Acta. Elsevier B.V.; 2020 [cited 2021 Mar 19]. p. 249–51. Available from: /pmc/articles/PMC7306200/
Henry BM, Aggarwal G, Wong J, Benoit S, Vikse J, Plebani M, et al. Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: A pooled analysis. Am J Emerg Med [Internet]. 2020 Sep 1 [cited 2021 Mar 19];38(9):1722–6. Available from: /pmc/articles/PMC7251362/